![Gianfranco Gilardi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gianfranco Gilardi
Corporate Officer/Principal presso The Royal Society of Chemistry
Posizioni attive di Gianfranco Gilardi
Società | Posizione | Inizio | Fine |
---|---|---|---|
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Corporate Officer/Principal | - | - |
University of Turin | Corporate Officer/Principal | - | - |
Storia della carriera di Gianfranco Gilardi
Precedenti posizioni note di Gianfranco Gilardi
Società | Posizione | Inizio | Fine |
---|---|---|---|
NanoBioDesign Ltd.
![]() NanoBioDesign Ltd. Pharmaceuticals: MajorHealth Technology NanoBioDesign is a life science company developing a commercializing a novel approach to CYP P450 testing based upon the patented concept of 'molecular lego'. NBD's electrochemical array technology produces high information content data relating to how a chemical entity interacts with a CYP P450 and also allows complex drug-drug interaction to be studied quickly and cost effectively. NBD was formed in 2001 as a spin out from Imperial College, London and has research and development activities based at Imperial College and also at the University of Turin, Italy. NBD has an experienced management team and board of directors as well as a dedicated group of investors who are committed to delivering its new paradigm in CYP P450 testing to the marketplace. | Direttore Tecnico/Scientifico/R&S | 01/01/2001 | 06/12/2012 |
Fondatore | 08/01/2010 | 06/12/2012 |
Statistiche
Distribuzione geografica
Regno Unito | 3 |
Italia | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Settori
Commercial Services | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Commercial Services |
NanoBioDesign Ltd.
![]() NanoBioDesign Ltd. Pharmaceuticals: MajorHealth Technology NanoBioDesign is a life science company developing a commercializing a novel approach to CYP P450 testing based upon the patented concept of 'molecular lego'. NBD's electrochemical array technology produces high information content data relating to how a chemical entity interacts with a CYP P450 and also allows complex drug-drug interaction to be studied quickly and cost effectively. NBD was formed in 2001 as a spin out from Imperial College, London and has research and development activities based at Imperial College and also at the University of Turin, Italy. NBD has an experienced management team and board of directors as well as a dedicated group of investors who are committed to delivering its new paradigm in CYP P450 testing to the marketplace. | Health Technology |
- Borsa valori
- Insiders
- Gianfranco Gilardi
- Esperienza